Neurogene Inc. (NGNE)

Market Cap	499.22M
Revenue (ttm)	n/a
Net Income (ttm)	-39.03M
Shares Out	12.98M
EPS (ttm)	6.93
PE Ratio	5.55
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	299,741
Open	40.44
Previous Close	40.62
Day's Range	36.89 - 42.52
52-Week Range	12.20 - 53.00
Beta	n/a
Analysts	Strong Buy
Price Target	49.40 (+28.45%)
Earnings Date	Aug 15, 2024

About NGNE

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquarter...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 91
• Stock Exchange: NASDAQ
• Ticker Symbol: NGNE

Analyst Forecast

According to 6 analysts, the average rating for NGNE stock is "Strong Buy." The 12-month stock price forecast is $49.4, which is an increase of 28.45% from the latest price.

Price Target

$49.4

(28.45% upside)

Analyst Consensus: Strong Buy